Skip to main content
Top
Published in: Familial Cancer 4/2009

01-12-2009

Younger age-at-diagnosis for familial malignant testicular germ cell tumor

Authors: Phuong L. Mai, Bingshu E. Chen, Kathy Tucker, Michael Friedlander, Kelly-Anne Phillips, David Hogg, Michael A. S. Jewett, Istvan Bodrogi, Lajos Geczi, Edith Olah, Ketil Heimdal, Sophie D. Fosså, Katherine L. Nathanson, Larissa Korde, Douglas F. Easton, Darshna Dudakia, Robert Huddart, Michael R. Stratton, D. Timothy Bishop, Elizabeth A. Rapley, Mark H. Greene

Published in: Familial Cancer | Issue 4/2009

Login to get access

Abstract

One of the clinical hallmarks of hereditary cancer susceptibility disorders is a younger-than-usual age at diagnosis. Familial aggregation of testicular germ cell tumor (TGCT) has been reported, but data on whether familial TGCT cases are diagnosed at an earlier age are inconclusive. Here we compared the age at diagnosis of familial TGCT cases with that of population cases in several countries. Familial TGCT is defined as affected individuals from families with ≥2 cases of TGCT. Age at diagnosis of familial cases from the United States, Canada, United Kingdom, Australia and New Zealand, Norway, and Hungary was compared to cases identified in population-based cancer registries from the respective country, using the generalized estimation equation method. Age at diagnosis was statistically significantly younger for familial TGCT cases from North America (P = 0.024), the United Kingdom (P < 0.0001), and Australia and New Zealand (P = 0.0033) compared with population cases. When stratified by histology, the difference in age at diagnosis distribution between familial and population cases was observed for seminoma cases from North America (P = 0.002) and the United Kingdom (P < 0.0001) and non-seminoma cases from the United Kingdom (P = 0.029) and Australia and New Zealand (P = 0.0023). In summary, we found that the age at diagnosis for familial TGCT cases is, on the average, 2–3 years younger than that for the population cases in North America, United Kingdom, and Australia and New Zealand. The younger age at diagnosis might be suggestive of a genetic basis for familial TGCT.
Literature
1.
go back to reference Ferlay J, Bray F, Pisani P et al (eds) (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Press, Lyon Ferlay J, Bray F, Pisani P et al (eds) (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Press, Lyon
2.
go back to reference Hemminki K, Sundquist J, Bermejo JL (2008) Familial risks for cancer as the basis for evidence-based clinical referral and counseling. Oncologist 13:239–247CrossRefPubMed Hemminki K, Sundquist J, Bermejo JL (2008) Familial risks for cancer as the basis for evidence-based clinical referral and counseling. Oncologist 13:239–247CrossRefPubMed
3.
go back to reference Holzik MFL, Rapley EA, Hoekstra HJ et al (2004) Genetic predisposition to testicular germ-cell tumours. Lancet Oncol 5:363–371CrossRef Holzik MFL, Rapley EA, Hoekstra HJ et al (2004) Genetic predisposition to testicular germ-cell tumours. Lancet Oncol 5:363–371CrossRef
4.
go back to reference Nicholson PW, Harland SJ (1995) Inheritance and testicular cancer. Br J Cancer 71:421–426PubMed Nicholson PW, Harland SJ (1995) Inheritance and testicular cancer. Br J Cancer 71:421–426PubMed
5.
go back to reference Heimdal K, Olsson H, Tretli S et al (1997) A segregation analysis of testicular cancer based on Norwegian and Swedish families. Br J Cancer 75:1084–1087PubMed Heimdal K, Olsson H, Tretli S et al (1997) A segregation analysis of testicular cancer based on Norwegian and Swedish families. Br J Cancer 75:1084–1087PubMed
6.
go back to reference Harland SJ, Daugaard G, Horwich A et al (2006) The familial influence on bilateral testicular germ cell cancer: medical Research Council study TER2. Annual Meeting Proceedings. J Clin Oncol 24, Abstract no. 4590 Harland SJ, Daugaard G, Horwich A et al (2006) The familial influence on bilateral testicular germ cell cancer: medical Research Council study TER2. Annual Meeting Proceedings. J Clin Oncol 24, Abstract no. 4590
7.
go back to reference Crockford GP, Linger R, Hockley S et al (2006) Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet 15:443–451CrossRefPubMed Crockford GP, Linger R, Hockley S et al (2006) Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet 15:443–451CrossRefPubMed
8.
go back to reference Rapley EA, Crockford GP, Easton DF et al (2003) Localisation of susceptibility genes for familial testicular germ cell tumour. APMIS 111:128–135CrossRefPubMed Rapley EA, Crockford GP, Easton DF et al (2003) Localisation of susceptibility genes for familial testicular germ cell tumour. APMIS 111:128–135CrossRefPubMed
9.
go back to reference Knudson AG Jr (1985) Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 45:1437–1443PubMed Knudson AG Jr (1985) Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 45:1437–1443PubMed
10.
go back to reference Lindor NM, McMaster ML, Lindor CJ et al (2008) Concise handbook of familial cancer susceptibility syndromes—second edition. J Natl Cancer Inst Monogr 2008:3–93CrossRef Lindor NM, McMaster ML, Lindor CJ et al (2008) Concise handbook of familial cancer susceptibility syndromes—second edition. J Natl Cancer Inst Monogr 2008:3–93CrossRef
11.
go back to reference Forman D, Oliver RT, Brett AR et al (1992) Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br J Cancer 65:255–262PubMed Forman D, Oliver RT, Brett AR et al (1992) Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br J Cancer 65:255–262PubMed
12.
go back to reference Dieckmann K-P, Pichlmeier U (1997) The prevalence of familial testicular cancer. Cancer 80:1954–1960CrossRefPubMed Dieckmann K-P, Pichlmeier U (1997) The prevalence of familial testicular cancer. Cancer 80:1954–1960CrossRefPubMed
13.
go back to reference Sonneveld DJA, Sleijfer DT, Schraffordt Koops H et al (1999) Familial testicular cancer in a single-centre population. Eur J Cancer 35:1368–1373CrossRefPubMed Sonneveld DJA, Sleijfer DT, Schraffordt Koops H et al (1999) Familial testicular cancer in a single-centre population. Eur J Cancer 35:1368–1373CrossRefPubMed
14.
go back to reference Dong C, Lonnstedt I, Hemminki K (2001) Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer 37:1878–1885CrossRefPubMed Dong C, Lonnstedt I, Hemminki K (2001) Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer 37:1878–1885CrossRefPubMed
15.
go back to reference Mai PL, Friedlander M, Tucker K et al. (2009) The international testicular cancer linkage consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol. doi:10.1016/J.urolonc.2008.10.004 Mai PL, Friedlander M, Tucker K et al. (2009) The international testicular cancer linkage consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol. doi:10.​1016/​J.​urolonc.​2008.​10.​004
17.
go back to reference Fossa SD, Chen J, Schonfeld SJ et al (2005) Risk of contralateral testicular cancer: a population-based study of 29 515 U.S. men. J Natl Cancer Inst 97:1056–1066PubMedCrossRef Fossa SD, Chen J, Schonfeld SJ et al (2005) Risk of contralateral testicular cancer: a population-based study of 29 515 U.S. men. J Natl Cancer Inst 97:1056–1066PubMedCrossRef
18.
go back to reference The International Testicular Cancer Linkage Consortium (1998) Candidate regions for testicular cancer susceptibility genes. APMIS 106:64–72CrossRef The International Testicular Cancer Linkage Consortium (1998) Candidate regions for testicular cancer susceptibility genes. APMIS 106:64–72CrossRef
19.
go back to reference Parzen E (1962) On estimation of a probability density function and mode. Ann Math Stat 33:1065–1076CrossRef Parzen E (1962) On estimation of a probability density function and mode. Ann Math Stat 33:1065–1076CrossRef
20.
go back to reference Liang K-Y, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13–22CrossRef Liang K-Y, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13–22CrossRef
21.
go back to reference McCullagh P, Nelder JA (1989) Generalized linear models, 2nd edn. Chapman and Hall/CRC, London McCullagh P, Nelder JA (1989) Generalized linear models, 2nd edn. Chapman and Hall/CRC, London
22.
go back to reference Smith RA, Cokkinides V, Brawley OW (2008) Cancer screening in the United States, 2008: a review of current American cancer society guidelines and cancer screening issues. CA Cancer J Clin 58:161–179CrossRefPubMed Smith RA, Cokkinides V, Brawley OW (2008) Cancer screening in the United States, 2008: a review of current American cancer society guidelines and cancer screening issues. CA Cancer J Clin 58:161–179CrossRefPubMed
Metadata
Title
Younger age-at-diagnosis for familial malignant testicular germ cell tumor
Authors
Phuong L. Mai
Bingshu E. Chen
Kathy Tucker
Michael Friedlander
Kelly-Anne Phillips
David Hogg
Michael A. S. Jewett
Istvan Bodrogi
Lajos Geczi
Edith Olah
Ketil Heimdal
Sophie D. Fosså
Katherine L. Nathanson
Larissa Korde
Douglas F. Easton
Darshna Dudakia
Robert Huddart
Michael R. Stratton
D. Timothy Bishop
Elizabeth A. Rapley
Mark H. Greene
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2009
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9264-6

Other articles of this Issue 4/2009

Familial Cancer 4/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine